Sanofi Ventures — Full Portfolio

Fulcrum Therapeutics develops small-molecule drugs targeting rare genetic diseases with significant unmet treatment needs, with its lead candidate pociredir in clinical testing for sickle cell disease as an oral therapy designed to increase fetal hemoglobin levels.

BiotechCambridge, US

Robert Gould(Executive Officer, Director)inACAlex C. Sapir(President and Chief Executive Officer, Director)in

BoardAEAlan Ezekowitz(Director)inMLMark Levin(Director)inJames Geraghty(Director)James Collins(Director)

Co-investorsFOForesite CapitalTHThird Rock Ventures

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

NMNello Mainolfi(Founder)inBBBruce Booth(Chair)in

Co-investorsATAtlas VentureAVAvoro Capital AdvisorsBABain Capital Life SciencesBEBessemer Venture PartnersHAHatteras Venture PartnersMRMRL Ventures Fund+7 more

MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients.

BiotechHealthtechMedical Devices

Scott Koenig(Director)inEREric Risser(President and Chief Executive Officer)in

Co-investorsHAHavencrest Capital ManagementRIRidgeback CapitalRIRiverVest Venture PartnersSASaints CapitalLALa CaisseTPTPG

Omada Health provides virtual-first, integrated care programs for chronic disease management, delivered as data-driven solutions for employers, health plans, and healthcare organizations.

Digital HealthHealthtechWellness & FitnessSan Francisco, US

Andrew DiMichelle(Executive Officer, Director)Adrian James(Founder)inSDSean Duffy(Founder)inWSWei-Li Shao(President)inSCSteve Cook(Chief Financial Officer)inAndrew DiMichele(Founder)

Co-investorsAMaMoonANAndreessen HorowitzBLBlackbird VenturesCACanvas VenturesCICivilization Ventures Management, LlcDEDesigner Fund+18 more

Ovid Therapeutics develops medicines for children and adults with epilepsies and brain conditions, focusing on anti-seizure and neurological treatments.

BiotechHealthtechMedical DevicesNew York, US

MJMatthew J. During(Executive Officer, Director)inJMJeremy M. Levin(Co-founder and Executive Chairman)inMAMeg Alexander(President & Chief Executive Officer)inCCCharles Carter(Chief Financial Officer)inVFVictoria Fort(Chief Strategy Officer)inPKPetra Kaufmann(Chief Medical Officer)in

Co-investorsBIBioBrit

Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.

BiotechHealthtech

SVShelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)JMJodie Morrison(Chief Executive Officer)inLKLee Kalowski(President & Chief Financial Officer)MMMaria Marzilli(Chief Business Officer)inDADavid Appugliese(Senior Vice President, Head of People)in

Co-investorsATAtlas VentureOROrbiMedAGAgent CapitalCUCU Healthcare Innovation FundOUOUP (Osage University Partners)5A5AM Ventures+2 more

Cogent Biosciences is a biotechnology company developing small molecule precision therapies for genetically driven diseases where the cause is linked to a specific genetic mutation.

BiotechDigital HealthHealthtechLongevityMedical DevicesCambridge, US

Charles Wilson(Executive Officer, Director)CSChristiana Stamoulis(Executive Officer)inAndrew Robbins(Chief Executive Officer, President and Director)inJohn Green(Chief Financial Officer)inEKEvan Kearns(Chief Legal Officer and Corporate Secretary)inCole Pinnow(Chief Commercial Officer)in

Co-investorsATAtlas VentureF-F-Prime Capital

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Founder)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Board seatJPJason P. Hafler· per SEC Form D

Co-investorsBABain Capital Life SciencesNENew Enterprise Associates (NEA)RARA CapitalSASamsara BioCapitalMAMass General Brigham VenturesREREDMILE+9 more

Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.

BiotechHealthtech

FMFrédéric Marrache(Co-founder & CEO)in

Co-investorsJEJeito CapitalSOSofinnova PartnersVIVIVES PartnersAPApollo Health VenturesSISixty Degree Capital

Character Bio is a patient-driven therapeutics company that combines genomics, longitudinal clinical and imaging data, and machine learning to identify genetic drivers of disease progression and develop new treatments, with a focus on polygenic diseases.

AI & Machine LearningBiotechDigital HealthJersey City, US

CZCheng Zhang(CEO, Co-Founder)inMarcel van der Brug(Scientific Advisor, Co-Founder)inNick Johnson(Technology Advisor, Co-Founder)inDEDaniel Elgort(Chief Data and Analytics Officer)inLCLaura Carter(Chief Scientific Officer)inRobert Kim(Chief Medical Officer)in

Co-investorsAMaMoonLULuma GroupINInnovation EndeavorsCACantos VenturesCACatalio Capital Management, LPDUDuke Capital Partners+5 more

Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.

BiotechDeep TechDigital HealthMedical DevicesCardiff, GB

John Atack(Head of Biology & Founder)inSWSimon Ward(Chief Scientific Officer & Founder)in

Co-investorsACAccess BiotechnologyCACanaan PartnersSVSV Health InvestorsSRSR One Capital ManagementBRBritish Business BankJAJanus Henderson Investors

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.

BiotechMedical DevicesBasel, CH

PLPatrick Loustau(President and Chief Executive Officer)in

Co-investorsNONovartis Venture FundFOForbionVEVersant Ventures

Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.

BiotechDeep TechHealthtechBurlington, MA, US

JRJay Rothstein, Ph.D.(Scientific Co-Founder and Advisor)AOArthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)Arthur Tzianabos, Ph.D.(President & Chief Executive Officer)

Co-investorsARARCH Venture PartnersATAtlas Venture5A5AM Ventures

MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.

BiotechHealthtech

PerBengt(CSO)

Co-investorsADAdjuvant CapitalINIndustrifondenOROrbiMedPUPureos BioventuresSUSunstone CapitalEQEQT Life Sciences+2 more

Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.

BiotechHealthtech

RHRachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)MKMitchell Keegan(Chief Development Officer)inWLWilliam LaRochelle(Chief Scientific Officer)inSMStacy M. Plum(Chief Technology Officer)

Co-investorsTATaiho Ventures, LLCPFPfizer VenturesSASamsara BioCapitalCACanaan PartnersCOConnecticut InnovationsOUOUP (Osage University Partners)+6 more

OMass is a biotech company that originated as a spinout from Oxford University, developing specialized treatments for patient populations with high unmet medical needs.

BiotechDeep TechDigital HealthHealthtechMedical DevicesOxford, GB

PDProfessor Dame Carol Robinson(Founder and Chair of Scientific Advisory Board)ILIdlir Liko(Founder)inJHJonathan Hopper(Vice President, Platforms and Founder)inHYHsin Yung (Jason) Yen(Founder)inRDRos Deeganin

Co-investorsGVGV (Google Ventures)OXOxford Science EnterprisesNONorthpond Ventures

QuantX Bio applies a proprietary computational platform to accelerate the discovery and optimization of drug candidates.

AI & Machine LearningBiotechDeep Tech

Co-investorsOROrbiMedCRCreacion VenturesLILilly Asia Ventures

SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.

BiotechDeep TechDigital HealthBarcelona, ES

DVDr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)

Co-investorsASAsabys PartnersNONovartis Venture FundRORoche Venture FundYSYsios CapitalCRCriteria Bio VenturesNENew Enterprise Associates (NEA)+3 more

Therini Bio is a biotechnology company developing fibrin-targeting therapeutics to treat neurological and ophthalmological diseases, leveraging scientific discoveries in neurovascular and neuroimmune mechanisms of disease.

BiotechDigital HealthHealthtechMedical DevicesSacramento, US

KAKaterina Akassoglou(Scientific Founder, Director of the Center for Neurovascular Brain Immunology and Professor of Neurology at UCSF and Gladstone Institutes)inKAKaterina Akassoglou, PhD(Scientific Founder)LSLeslie Schulze(Executive Officer)TNTara Nickerson(Executive Officer, Director)in

BoardODOlga Danilchanka(Director)inLaia Crespo-Martin(Director)

Co-investorsMRMRL Ventures FundSVSV Health InvestorsANAngelini VenturesDEDementia Discovery FundDODolby Family VenturesMIMitsui Global Investment+2 more

Tisento develops pharmaceutical treatments for complex genetic mitochondrial diseases, beginning with MELAS.

BiotechLongevity

PHPeter Hecht, PhD(Chief Executive Officer)Peter Hecht(Founder)

Co-investorsVEVenrock

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.

BiotechHealthtechMedical DevicesCambridge, US

AAAndrew Adamovich(Director)inPLPhilina Lee(Executive Officer, Director)inAPAaron Pickett(Executive Officer)in

BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)

Board seatCGChristopher Gagliardi· per SEC Form D

Co-investorsBABain Capital Life SciencesCACatalio Capital Management, LPPRProto AxiomSVSV Health InvestorsTETenmileABAbingworth+2 more

Click Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy.

BiotechDigital HealthHealthtechMedical DevicesNew York, US

DBDavid B. Klein(Founder and CEO)inRSRandall Stanicky(Executive Officer)inAnthony Costello(Director)Bruce Robertson(Director)Douglas Langa(Director)

BoardAlex Zisson(Director)

Board seatCDCris De Luca· per SEC Form D

Co-investorsACAccelmed PartnersH.H.I.G. CapitalH.H.I.G. HealthBridge PartnersHEHealth Catalyst CapitalHIHikma VenturesRERevelation Partners+5 more

Company developing molecules targeting a novel class of receptors for neuro-immuno-inflammatory diseases; acquired by Incyte in May 2024.

BiotechSan Diego, US

Alain Baron(Founder)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Founder)

BoardASAndrew Schwab(Director)in

Board seatJPJason P. Hafler· per SEC Form D

Co-investors5A5AM VenturesAVAvego BioScience CapitalNENew Enterprise Associates (NEA)OUOUP (Osage University Partners)THThe Column GroupABAbingworth+3 more

Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.

BiotechCambridge, US

Andre Turenne(Executive Officer, Director)in

BoardJHJason Hafler(Director)inBruce Booth(Director)Daniel Becker(Director)

Board seatJPJason P. Hafler· per SEC Form D

Co-investorsACAccess BiotechnologyDIDigitalis VenturesACAccess IndustriesALAlexandriaATAtlas Venture

Star Therapeutics develops treatments aimed at addressing real-world patient needs.

BiotechSouth San Francisco, US

ARAdam Rosenthal(Founder & CEO)inNSNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)SRScott Robertson(Executive Officer)inGary Patou(Executive Officer)in

Board seatJPJason P. Hafler· per SEC Form D

Co-investorsFRFrazier Life SciencesOROrbiMedRARA CapitalSOSofinnova VenturesVIViking GlobalAGAgent Capital+11 more

Healthcare technology company delivering real-world evidence for life sciences companies, payers, and regulators.

Data & InfrastructureDigital HealthHealthtechNew York, US

Sebastian G. Schneeweiss(Director)WGWilliam Geary(Director)inJeremy Rassen(Founder)KAKyle Armbrester(Chief Executive Officer)inSebastian Schneeweiss(Founder)

Co-investorsB B Capital GroupB4B4 CapitalBLBlue LionBLBlue Lion GlobalFLFlare Capital PartnersFOForesite Capital+8 more

AgelessRx offers prescription weight management medications delivered through a telehealth platform, including GLP-1 medications (semaglutide, tirzepatide), FDA-approved weight loss drugs (Wegovy, Zepbound), and supportive treatments like metformin and vitamin injections for adults seeking medically-supervised weight loss.

BiotechDigital HealthDirect to ConsumerHealthtechLongevityAnn Arbor, US

AIAnar Isman(Co-Founder & Chief Executive Officer)inRobert Michael Pejovich(Director of Finance of the Issuer)

Co-investors1/1/1 CapitalABabrdn plcANAngelini VenturesFIFidelity InvestmentsJAJanus Henderson Investors

Altesa BioSciences is a clinical-stage pharmaceutical company developing vapendavir, an orally administered antiviral targeting rhinovirus infections in patients with chronic lung diseases such as COPD and asthma.

BiotechHealthtechCollege Park, US

JCJohn Clerici(Executive Officer)inAndrew Drechsler(Executive Officer)Brett Giroir(Executive Officer, Director)

BoardNWNicholas Williams(Director)MSMoncef Slaoui(Director)JEJon Edwards(Director)in

Co-investorsGRGRA VentureFOForbionMEMedicxiPIPitango

Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.

BiotechChapel Hill, US

RWRobin Walker(Executive Officer)inChristopher Courts(Executive Officer)inJorge Bartolome(Founder)in

BoardBenjamin Gomez(Director)AKAdam Koppel(Director)inMichael E. Bozik(Director)

Co-investorsARARCH Venture PartnersBABain Capital Life SciencesGVGV (Google Ventures)SOSolas BioVenturesVIViking GlobalACAccess Biotechnology+3 more

Atalanta is developing treatment options for intractable central nervous system diseases using RNA interference technology.

BiotechDeep TechHealthtechMedical Devices

Co-investorsF-F-Prime CapitalNONovartis Venture FundRIRiverVest Venture PartnersABabrdn plcEQEQT Life Sciences

Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.

BiotechDigital Health

ZOZaneta Odrowaz(Founder)inTFTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)ZOZaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)

Co-investorsECEcoR1 CapitalFRFrazier Life SciencesILIllumina VenturesNENextech InvestVIVida VenturesGOGoldman Sachs+1 more

Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process.

BiotechWaltham, US

THERESA CAMERON(Director)MFMARTIN FREED(Director)inSTEPHANIE TOZZO(Executive Officer)PHIL GRAHAM(Executive Officer)MDMILIND DESHPANDE(Director)DAVID NEAFUS(Executive Officer)

Co-investorsASAstellas Venture Management LLCMEMedical Excellence CapitalRARA CapitalOPOpenSky Ventures

Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.

BiotechLongevityMedical DevicesCambridge, US

DMDavid Meek(Chief Executive Officer)inBRBrian Riley(President & Chief Technical Officer)inJLJoanne Lager(Chief Medical Officer)inWDWendy DiCicco(Chief Financial Officer)inACAdrian Chaisson(Chief of Staff)inJCJason Cole(Executive Officer)

Co-investorsARARCH Venture PartnersEAEaston CapitalRARA CapitalTHThink+ Ventures Management, LlcWAWakestream VenturesFOForbion+1 more

Branchlab offers an AI-driven platform for healthcare marketing that helps teams explore patient, HCP, and caregiver audiences without exposing Protected Health Information, then create, optimize, and activate those audiences across channels.

AI & Machine LearningHealthtechMarketing TechNew York, US

Joshua Walsh(Executive Officer, Director)Christopher Cagle(Executive Officer, Director)

BoardMPMichael Parkes(Director)inCWCarrie Williams(Director)inABAndrew Bouldin(Director)in

Co-investorsAIAIX VenturesFCFCA Venture PartnersMCMcKesson VenturesNENext VenturesNVNVP CapitalSEService Provider Capital+2 more

Carbon Health operates a chain of clinics offering urgent care, primary care, and chronic condition management, combining technology with in-person care to provide broader access to health services.

Digital HealthHealthtechMedia & Entertainment

EBEren Bali(Founder)inGBGreg Burrell(Founder)inTom Berry(Founder)Caesar Djavaherian(Founder)Greg Burell(Founder)

Co-investors50500 Emerging Europe50500 Global51515 VenturesAKAkkadian VenturesANAnnex InvestmentsBUBuilders VC+30 more

HealthtechCambridge, US

Richard Whalley(Executive Officer, Director)James White(Executive Officer, Director)

BoardPatrick Flynn(Director)

Co-investorsWAWaterline VenturesQUQualcomm Ventures

Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.

BiotechHealthtech

GSGeorge Simeon(CEO)inGregory S. Curhan(CFO)GDGuy De La Rosa(CMO)in

Co-investorsADAdjuvant CapitalOROrbiMedRARA CapitalHBHBM Healthcare InvestmentsJAJanus Henderson InvestorsMEMedicxi

Manhattan Beach, US

PKPeter Kim(Executive Officer, Director, Promoter)inFrancis Lam(Executive Officer, Director, Promoter)

BoardBGBill Geary(Director)inMMMohamad Makhzoumi(Director)in

Co-investorsFLFlare Capital PartnersGRGreen Bay VenturesNENew Enterprise Associates (NEA)SHShuttle Fund

Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.

AI & Machine LearningBiotechHealthtechWatertown, US

Alex Lugovskoy(Founder)Michael Gladstone(Founder)

Co-investorsATAtlas VentureECEcoR1 CapitalFRFrazier Life SciencesRARA CapitalRVRV Invest GmbHVIViking Global

Eligo Bioscience is a genetic engineering company pioneering synthetic biology approaches using CRISPR and phage biology to develop therapeutics.

AI & Machine LearningBiotechDeep TechHealthtechMedical Devices

David Bikard(Scientific Founder)Benoit Barteau(Scientific Cofounder)Nessan Bermingham(Scientific Cofounder)Laia Crespo-Martin(Scientific Cofounder)Xavier Duportet(CEO)

Co-investorsAGAgoranovNSNSG VenturesSESeventure PartnersVIVIVES Partners

Eligo Bioscience works on the role of bacterial genes in causing or aggravating disease, with a focus on genetic causality across therapeutic areas.

BiotechDeep TechHealthtech

David Bikard(Founder)Luciano Marraffini(Founder)Timothy Lu(Founder)Xavier Duportet(Founder)

Empatica offers an FDA-cleared health monitoring platform combining medical wearables and digital biomarkers to collect continuous, clinical-quality health data from daily life.

AI & Machine LearningDigital HealthHealthtechMedical DevicesCambridge, US

RPRosalind Picard(Founder)inMLMatteo Lai(Executive Officer, Director)inSTSimone Tognetti(Director)inLPLen Picard(Executive Officer, Director)inMario Scuderi(Director)

Co-investorsBLBlack Opal VenturesCDCDP Venture CapitalRARA CapitalINInnogest Capital

Enveda operates a drug-discovery platform that analyzes natural samples—primarily plant-derived molecules—using mass spectrometry, AI foundation models, and automated high-throughput labs to identify their chemical structures and therapeutic properties.

AI & Machine LearningBiotechDeep TechBoulder, US

VCViswa Colluru(Founder)inDaniel Wee(Executive Officer)Pieter Dorrestein(Founder)Viswa Colluru Pieter Dorrestein(Founder)

BoardRohit Sharma(Director)ZDZavain Dar(Director)in

Co-investorsAIAir Street CapitalBOBoulder VenturesCACatalio Capital Management, LPCOCox EnterprisesFPFPVHUHummingbird Ventures+20 more

Epic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US

Lei Stanley Qi(Scientific Founder)inASAmber Salzman(Executive Officer, Director)inHaorui Zhang(Executive Officer, Director)

BoardAndrew Lam(Director)Anran Li(Director)Jennifer King(Director)

Co-investorsALAlly Bridge GroupABabrdn plcANAngelini VenturesFIFidelity InvestmentsJAJanus Henderson Investors

Evidation collects and analyzes real-world health data from millions of community members to enable clinical research and health programs across various medical conditions.

BiotechData & InfrastructureDigital HealthHealthtechSan Francisco, US

CLChristine Lemke(Executive Officer, Director)inDKDeborah Kilpatrick(Executive Officer, Director)LOLeslie Oley Wilberforcein

BoardDavid Fleshman(Director)RCRowan Chapman(Director)in

Co-investorsASAsset Management CompanyB B Capital GroupB4B4 CapitalCRCross Creek AdvisorsDEDementia Discovery FundFRFresco Capital+6 more

Expedition Therapeutics is a drug development company focused on advancing therapeutic programs in areas such as CAR-T immunotherapy and oncology.

BiotechHealthtechMedical DevicesSan Francisco, US

Yi Larson(Founder and CEO)GGGeoff Gilmartin(Chief Medical Officer)EHEric Hu(Chief Business Officer)

Co-investorsFOForbionNONovo HoldingsSOSofinnova Ventures

Formation.Fi is a decentralized finance platform built on Ethereum that enables users to participate in liquidity provision, yield farming, and asset swapping through automated strategies and smart contracts.

Crypto & Web3Fintech

Co-investorsGEGenblock CapitalANAndreessen HorowitzLALachy GroomSESequoia CapitalTHThriveTHThrive Capital

Formation Bio develops drugs through partnerships with health systems, academic medical centers, and research sites, focusing on clinical trials in dermatology, rheumatology, and cardiometabolic diseases.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechMedical DevicesSaaSNew York, US

BLBen Liu(CEO & Co-Founder)inLZLinhao Zhang(Co-Founder)inBenjamine Liu(Founder)Kit Dobyns(Founder)Mary Rozenman(Founder)

BoardALAlfred Lin(Director)in

Co-investorsANAndreessen HorowitzSESequoia CapitalSASam AltmanSESection 32THThrive CapitalFEFelicis Ventures+11 more

Fulcrum Therapeutics develops small-molecule treatments targeting genetically defined rare diseases with high unmet medical need, using proprietary technology to modulate gene expression and address the root cause of gene mis-expression.

BiotechHealthtech

Alex C. Sapir(CEO)

GlycoMimetics is a company developing cancer therapies, aiming to advance treatment options for people living with cancer.

BiotechHealthtechWaltham, US

Co-investorsNENew Enterprise Associates (NEA)

Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.

BiotechSan Francisco, US

Agnes Rafalko(Executive Officer, Director)inSASteven Axon(Chief Executive Officer)inHAHicham Alaoui(Chief Scientific Officer)inRMRose Marino(Chief Medical Officer)inPMPeter McWilliams(Chief Business Officer)GHGeoffrey Hird(Chief Technology Officer)in

Co-investorsADAdvent Life SciencesASAsahi Kasei Corporate Venture CapitalCHChiesi VenturesCTCTI Life Sciences Fund L.P.MIMission Bay CapitalMIMission Biocapital+6 more

A biopharmaceutical company developing a pipeline of long-acting therapeutic candidates, including GLP-1 receptor agonists, amylin DACRAs, a PYY receptor agonist, and a glucagon receptor agonist.

BiotechSaratoga, US

MMMitragotri Mitragotri(Executive Officer, Director)RSRavi Srinivasan(Executive Officer, Director)in

Co-investors7G7G BioVenturesCECerity Partners VenturesCOColorcon VenturesHIHikma VenturesJDJDRF T1D Fund

Vaccine development platform using computationally designed synthetic virus-like particles

BiotechSeattle, US

Charles Richardson(Senior Vice President, Technical Operations)Adam K. Simpson(President and Chief Executive Officer)Niranjan Kanesa-thasan(Chief Medical Officer)Douglas A. Holtzman(Chief Scientific Officer and Secretary)Cassia Cearley(Treasurer, Chief Business Officer)

BoardPKPeter Kolchinsky(Director)in

Co-investorsQIQiming Venture Partners USARARA CapitalVIViking GlobalQIQiming HealthcareQIQiming Venture Partners

Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy.

BiotechDigital Health

ASAlvin Shih(CEO)inAMAlbert M. Kim(Chief Medical Officer)in

Co-investorsANAN Venture PartnersCACatalio Capital Management, LPRARA CapitalSVSV Health InvestorsCACatalio Capital Management

Immunotherapy oncology company engineering technologies to activate the immune system; acquired by Merck in February 2019 for $0.3B.

BiotechHealthtechMedical DevicesSeattle, US

DBDavid Baltimore(Director)Carlos V. Paya(Executive Officer, Director)Stephen R. Brady(Executive Officer)inJHJan Henrik ter Meulen(Executive Officer)Paul Rickey(Executive Officer)inWayne Gombotz(Executive Officer)in

Co-investorsAIAisling CapitalATAtlas VentureHMHM Venture PartnersOUOUP (Osage University Partners)SASanderling VenturesSPSPRINGROCK VENTURES+4 more

BiotechBoston, US

ABAxel Bolte(Executive Officer, Director)inReinaldo Diaz(Director)Joseph Schlessinger(Executive Officer, Director)

BoardEdward Mathers(Director)RHRob Hopfner(Director)inMartin Edwards(Director)

Co-investorsLOLongitude CapitalNENew Enterprise Associates (NEA)PIPivotal Life SciencesSOSofinnova Ventures

The page promotes "MEGA55", an Indonesian-language online gaming/gambling platform offering a variety of games with instant-win rewards and local digital payment methods.

Gaming

Co-investors5A5AM Ventures

Korsana develops technology to deliver large-molecule biologic drugs across the blood-brain barrier using transferrin receptor shuttling, aimed at treating neurodegenerative diseases such as Alzheimer's.

BiotechDeep TechHealthtechWaltham, US

MVMark Vignola(Chief Financial Officer)inJVJonathan Violin(President)in

Co-investorsTCTCG CrossoverWEWellington ManagementVEVenrock

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.

BiotechHealthtechMedical DevicesThousand Oaks, US

NFNima Farzan(Executive Officer, Director)TLTim Lugo(Executive Officer)Sean Harper Desmond Padhi(Founder)

BoardBSBeth Seidenberg(Director)inJTJim Tananbaum(Director)inDPDeborah Palestrant(Director)in

Co-investors5A5AM VenturesACAccess BiotechnologyASAscenta CapitalFOForesite CapitalKEKern Capital, LLCWEWestlake Village BioPartners

LAVA develops the Gammabody platform, which generates bispecific antibodies that activate gamma-delta T cells to treat cancer by directing immune cells to tumors and triggering anti-cancer immune responses.

AI & Machine LearningBiotechHealthtechMedical Devices

Ton AdanginHVHans van der Vliet(Head of Innovation)inSHSteve Hurly(Chief Executive Officer)OPOxana Polyakova(Chief Scientific Officer)in

Co-investorsMRMRL Ventures FundYSYsios CapitalGIGilde HealthcareNONovo HoldingsREREDMILE

Acquired by Shire in 2014 (now part of Takeda).

BiotechMedical Devices

Co-investorsFRFrazier Life SciencesLOLongitude CapitalOBOberland CapitalPAPappas CapitalRIRiverVest Venture Partners

Lysosomal Therapeutics Inc.

BiotechCambridge, US

Dimitri Krainc(Director)Robert Carpenter(Executive Officer, Director)Cornelis Been(Executive Officer, Director)

BoardSteven Hall(Director)Carole Nuechterlein(Director)inBernard Davitian(Director)

Co-investorsATAtlas VentureHAHatteras Venture PartnersLILilly VenturesOMOmega FundsRORoche Venture Fund

Matchpoint Therapeutics is a drug discovery company developing precision small molecule covalent medicines to treat immune and inflammatory diseases.

AI & Machine LearningBiotechDeep Tech

Andre TurenneJared Cumming(PhD)Christopher HrenThomas Durand-Reville(PhD)Wei Li(MD)Paola Castaldi(PhD)

Co-investorsATAtlas VentureDIDigitalis Ventures

Medisafe is a medication engagement platform that helps pharmaceutical companies connect with patients beyond the prescription and improve treatment adherence.

Digital HealthHealthtechMedical DevicesBoston, US

RSRotem Shor(Founder)in

Co-investors7W7wire VenturesALALIVE Israel HealthTech FundCOCorewell Health VenturesLOLool VenturesM M VenturesOCOctopus Ventures+3 more

Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach.

AI & Machine LearningHealthtechMedical DevicesSan Diego, US

MCMark C. McKenna(Executive Officer, Director)inJoseph Papa(Director)Scott Glenn(Director)Vika Brough(Executive Officer)Timothy K. Andrews(Executive Officer)Mark McKenna(Founder)

Co-investorsAQAquiline Technology GrowthARARCH Venture PartnersOROrbiMedINInvusPOPoint72VEVenrock Healthcare Capital Partners

Muna Therapeutics is a biotechnology company developing therapeutics, with a focus on drug discovery involving medicinal chemistry.

BiotechDeep TechHealthtechLongevity

RBRita Balice-Gordon(Founder)inJVJoachim Vilstrup(Head of Protein Chemistry and Structural Biology; scientific co-founder)inMDMichel Detheux(Chief Executive Officer & Board Director)inAHAnders Hinsby(Chief Operating Officer)inNPNiels Plath(Chief Scientific Officer)inJBJakob Busch-Petersen(Chief Development Officer)in

Co-investorsDRDroia VenturesSOSofinnova PartnersV-V-Bio Ventures

BiotechCambridge, US

Rick Lundberg(Executive Officer)GPGeorge P. Vlasuk(Executive Officer, Director)in

BoardJFJean-Francois Formela(Director)inACAlan Crane(Director)inMNMarian Nakada(Director)inBGBrian Gallagher(Director)in

Co-investorsAGage1BRBrace PharmaATAtlas VenturePOPolaris PartnersSRSR One Capital Management

NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.

BiotechHealthtechAustin, US

GFGordon Freeman(Scientific Founder)XZXingXing Zang(Scientific Founder)inICIvan Cheung(Chief Executive Officer)inLGLeena Gandhi(Chief Medical Officer)inTNTatiana Novobrantseva(Chief Scientific Officer)inAHAxel Hoos(Director)

Co-investorsCACatalio Capital Management, LPMPMPM BioImpactCACatalio Capital ManagementINInvusLELeaps by BayerSISixty Degree Capital

Avi Veidman(Founder)Eliron Amir(Founder)Lotan Chorev(Founder)

Co-investorsM M VenturesSASAV (Scale Asia Ventures)VEVertex Ventures IsraelDEDebiopharm Innovation FundGRGrove VenturesS3S32+1 more

Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.

BiotechDeep TechDigital HealthHealthtechMedical Devices

Co-investorsTHThe Column GroupSASamsara BioCapital

Nuvig Therapeutics develops immune-modulating medicines for autoimmune diseases by harnessing endogenous regulatory mechanisms to resolve immune dysregulation.

BiotechHealthtechMedical Devices

Pamela Conley(Founder)in

Co-investorsB B Capital GroupB4B4 CapitalGLGlobal BioAccess FundMIMission BiocapitalDIDigitalis VenturesNONorwest Venture Partners

Nuvig Therapeutics is a biotech company developing immune-modulating therapies for autoimmune and chronic inflammatory diseases, using an endogenous regulatory mechanism intended to treat inflammation without compromising broader immune function.

BiotechLongevity

Co-investorsABabrdn plcALAlexandriaB B CapitalDIDigitalis VenturesGLGlobal BioAccess FundLELeaps by Bayer+4 more

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.

BiotechMedical DevicesCambridge, US

GDGary D Glick(Executive Officer, Director)inGary D. Glick(Founder)

BoardJCJill Carroll(Director)inCGCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)

Co-investorsACActivant CapitalASAscenta CapitalBABalderton CapitalCACatalio Capital Management, LPFOForesite CapitalGLGlobal BioAccess Fund+9 more

Owkin develops AI Scientist, an autonomous AI system that uses biological large language models and multimodal patient data to accelerate drug discovery for pharmaceutical and biotech companies.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSilicon Valley, FR

TCThomas Clozel(Co-founder and Chief Executive Officer)inGWGilles Wainrib(Co-founder)inThomas Clozel Gilles Wainrib(Founder)

Co-investorsBRBridford Investments (Bridford Group)CACathay InnovationF-F-Prime CapitalFRFrstGVGV (Google Ventures)ALAlpha Intelligence Capital+3 more

Developing disease-modifying therapeutics for diseases of protein processing, with a lead program in cystic fibrosis.

Co-investorsAVAvoro Capital AdvisorsF-F-Prime CapitalNENew Enterprise Associates (NEA)SOSofinnova Ventures

QuantHealth provides clinical trial design optimization tools that help pharmaceutical and biotech companies evaluate trial outcomes, competitive positioning, and enrollment feasibility to reduce development risk and accelerate timelines.

AI & Machine LearningBiotechDigital HealthHealthtech

OIOrr Inbar(Founder)inArnon Horev(Founder)inOrr Inbar Arnon Horev(Founder)

Co-investorsISIsrael Innovation AuthorityATATOORO FUNDESEsplanade VenturesNINina CapitalNONovaCapitalPIPitango+1 more

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.

BiotechDeep TechMedical DevicesCambridge, US

KEKevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)KRKasper Roet(Director, Executive Officer, Promoter)inSVShafique Virani(Executive Officer)inJBJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in

Co-investorsALALS Investment FundDODolby Family VenturesDRDroia VenturesINInkefMCMC Healthcare VenturesMIMission Biocapital+8 more

ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)

Co-investorsAJAju IB InvestmentECEcoR1 CapitalEVEvolution VC PartnersMPMPM BioImpactOROrbiMedOUOUP (Osage University Partners)+6 more

NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation.

BiotechHealthtech

GMGeoff McDonough(Executive Team / Board)inCGChris Guiffre(Executive Team)inAPAlan P. Watt(Executive Team)inJGJyothis George(Chief Medical Officer)inNCNick Clarke(Executive Team)in

Co-investors5A5AM VenturesEPEpidarex CapitalF-F-Prime CapitalSOSofinnova Partners

Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.

Benjamin Greenbaum(Founder)David Ting(Founder)Rosana Kapeller(Founder)

Co-investorsANAndreessen HorowitzARARCH Venture PartnersGVGV (Google Ventures)LULuma GroupABAbingworthADAdvent Life Sciences+11 more

Science37 operates a decentralized clinical trial platform supported by a network of medical directors across specialties including cardiology, neurology, psychiatry, pediatrics, and internal medicine.

BiotechDigital HealthHealthtechMedical Devices

TVTyler Van Horn(Chief Executive Officer)inDWDebra Weinstein(Chief Medical Officer)in

Co-investorsGLGlynn Capital ManagementGVGV (Google Ventures)LILifeSci Venture PartnersLULux CapitalINInertia VenturesREREDMILE

Sensorion is a French clinical-stage biopharmaceutical company founded in 2009 in Montpellier that develops gene-therapy and small-molecule treatments for inner-ear disorders like genetic deafness and tinnitus.

Co-investorsSOSofinnova PartnersINInvusREREDMILE

Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.

BiotechHealthtechMedical DevicesMenlo Park, US

Jim Bristol(Director)DEDaniel Estes(Director)inSBScott Byrd(Executive Officer, Director)in

Co-investorsFRFrazier Life SciencesMOMonograph Capital PartnersPIPICUS CAPITALSVSV Health InvestorsDEDementia Discovery FundFRFrazier Healthcare Partners+2 more

T-Therapeutics develops T cell receptor-based therapeutics for cancer and autoimmune diseases using its proprietary OpTiMus platform, which identifies antigen-specific human TCRs.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, GB

Co-investorsCACambridge Innovation CapitalF-F-Prime CapitalSOSofinnova PartnersBUBusiness Growth FundDIDigitalis VenturesUNUniversity of Cambridge Enterprise

Developer of next-generation insulin solutions

BiotechWaban, US

Richard Berenson(Executive Officer, Director, Promoter)David C. Sweeney(Director)

BoardTXTim Xiao(Director)inJohn Brooks(Mr. Brooks is the Chairman of the Board of Directors.)

Co-investorsDEDelos CapitalRORobin Hood VenturesGRGreen Park & Golf VenturesJUJumpstart Ventures

Sanofi is an R&D-driven, AI-powered biopharmaceutical company that develops medicines and vaccines, with a focus on immunology and the immune system.

AI & Machine LearningBiotechHealthtech

Co-investorsMRMRL Ventures FundNENew Enterprise Associates (NEA)RHRho VenturesFJFJ Labs

Trial Library operates an AI-native platform that integrates clinical trials into routine care, activating providers, identifying eligible patients, and guiding them through the trial lifecycle.

AI & Machine LearningDigital HealthHealthtech

Co-investorsHOHow Women InvestLULux CapitalNENext VenturesOVOverwater Ventures LlcSESeae VenturesSESemperVirens Venture Capital+1 more

Ultragenyx is a biotechnology company focused on developing treatments for patients living with rare genetic diseases.

BiotechHealthtechMedical Devices

Co-investorsF-F-Prime CapitalPAPappas Capital

Unspun develops 3D weaving technology and software for apparel and textile manufacturing, enabling fast, automated, and low-waste garment production for brands and manufacturers.

Advanced ManufacturingCleantechClimate TechEmeryville, US

Walden Hoi Ming Lam(Executive Officer, Director)BEBeth Esponnette(Founder)inKMKevin Martin(Founder)inAAARNE ARENS(Executive Officer, Director)inWalden Lam(Founder)

BoardMWMilo Werner(Director)in

Co-investorsALAlumni VenturesCICity LightDCDCVC (Data Collective)E1E12 Venture Capital, LlcEVEvolution VenturesFIFifty Years+10 more

Cogent Biosciences is a biotechnology company developing small molecule precision therapies for genetically driven diseases where a specific genetic mutation is the underlying cause.

BiotechHealthtechBoulder, US

Co-investorsWEWellington Management

Developing novel treatments based on the 12-LOX pathway for immuno-inflammatory diseases.

Co-investorsALAlumni VenturesHAHatteras Venture PartnersPAPappas CapitalALAlexandriaGEGenesys CapitalJDJDRF T1D Fund+4 more

Aptar Digital Health is a division of Aptar Pharma that designs and manufactures drug delivery systems and digital health solutions for the pharmaceutical and healthcare industries.

Digital HealthHealthtechMedical DevicesSaaS

Co-investorsCACapDecisif ManagementEIEisai Innovation, Inc.KAKaristaVEVesalius Biocapital Partners

Windward delivers AI-powered operational intelligence for maritime security and commercial applications, fusing behavioral analytics and multi-sensor data to detect threats and opportunities.

AI & Machine LearningData & InfrastructureDefense TechTel Aviv

Amiad Daniel(Executive Officer, Director)MPMatan Peled(Founder)inAmi Daniel(Founder)

BoardDov Gatmon(Director)Patrick Poon(Director)ESEden Shochat(Director)in

Co-investorsALAlephFTFTV CapitalTHThompson Hutton, LLCJAJanus Henderson InvestorsPIPivotal Life SciencesQIQiming Venture Partners+3 more

Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.

BiotechHealthtech

Co-investorsOROrbiMedQUQuan CapitalRARA CapitalSRSR One Capital ManagementJAJanus Henderson InvestorsNONovo Holdings+3 more

Zag Bio develops thymus-targeted bifunctional antibodies designed to induce central tolerance for treating autoimmune diseases.

BiotechDeep TechHealthtechMedical DevicesCambridge, US

Alan Crane(Founder)Diane Mathis(Founder)Joanne Lim(Co-founder)Dr. Diane Mathis(Founder)Jo Viney(Founder)John Kulman(Founder)

Co-investorsLILightspeed Venture PartnersMIMission BiocapitalPEPear VCPOPolaris PartnersTHThe Engine Ventures